NASDAQ : RPRX
Royalty Pharma plc — Key statistics
Healthcare · Biotechnology · United States
Last price 67.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 38.63B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 38.25B |
| Enterprise Value | 46.37B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Nov 13, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 445.28M |
| Shares Outstanding | 575.00M |
| Shares Change (YoY) | -3.88% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 6.10% |
| Owned by Institutions (%) | 85.57% |
| Float | 417.57M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 35.68 |
| Forward PE | 12.07 |
| PS Ratio | 15.08 |
| Forward PS | 10.51 |
| PB Ratio | 4.38 |
| P/TBV Ratio | 6.47 |
| P/FCF Ratio | 12.85 |
| P/OCF Ratio | 12.85 |
| PEG Ratio | 1.64 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 57.11 |
| EV / Sales | 18.29 |
| EV / EBITDA | 29.78 |
| EV / EBIT | 29.87 |
| EV / FCF | 15.58 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.80 |
| Quick Ratio | 2.79 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 5.75 |
| Debt / FCF | 3.01 |
| Interest Coverage | 4.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 13.97% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 5.35% |
| Return on Capital Employed (ROCE) | 8.09% |
| Weighted Average Cost of Capital (WACC) | 5.65% |
| Revenue Per Employee | $25.36M |
| Profits Per Employee | $8.12M |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +78.02% |
| 50-Day Moving Average | 60.39 |
| 200-Day Moving Average | 53.36 |
| Relative Strength Index (RSI) | 74.26 |
| Average Volume (20 Days) | 3,130,736 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.84M |
| Short Previous Month | 12.89M |
| Short % of Shares Out | 2.23% |
| Short % of Float | 3.08% |
| Short Ratio (days to cover) | 4.30 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.54B |
| Gross Profit | 2.43B |
| Operating Income | 1.55B |
| Pretax Income | 1.35B |
| Net Income | 811.99M |
| EBITDA | 1.56B |
| EBIT | 1.55B |
| Earnings Per Share (EPS) | $1.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 836.99M |
| Total Debt | 8.96B |
| Net Cash | -8.12B |
| Net Cash Per Share | -$14.13 |
| Equity (Book Value) | 9.79B |
| Book Value Per Share | 15.33 |
| Working Capital | 1.13B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 2.98B |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.94M |
| Net Borrowing | 954.48M |
| Free Cash Flow | 2.98B |
| FCF Per Share | $5.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 95.82% |
| Operating Margin | 61.22% |
| Pretax Margin | 53.11% |
| Profit Margin | 32.02% |
| EBITDA Margin | 61.41% |
| EBIT Margin | 61.22% |
| FCF Margin | 117.37% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.94 |
| Dividend Yield | 1.41% |
| Dividend Growth (YoY) | 6.82% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 50.42% |
| FCF Payout Ratio | 18.16% |
| Buyback Yield | 3.88% |
| Shareholder Yield | 5.30% |
| Earnings Yield | 2.80% |
| FCF Yield | 7.78% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $65.38 |
| Price Target Difference | -1.71% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 20.58% |
| EPS Growth Forecast (3Y) | 10.61% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.73 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |